Tbio HSPG2 Basement membrane-specific heparan sulfate proteoglycan core protein

Protein Summary

Description

Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development. Endorepellin in an anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6. The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity. This gene encodes the perlecan protein, which consists of a core protein to which three long chains of glycosaminoglycans (heparan sulfate or chondroitin sulfate) are attached. The perlecan protein is a large multidomain proteoglycan that binds to and cross-links many extracellular matrix components and cell-surface molecules. It has been shown that this protein interacts with laminin, prolargin, collagen type IV, FGFBP1, FBLN2, FGF7 and transthyretin, etc., and it plays essential roles in multiple biological activities. Perlecan is a key component of the vascular extracellular matrix, where it helps to maintain the endothelial barrier function. It is a potent inhibitor of smooth muscle cell proliferation and is thus thought to help maintain vascular homeostasis. It can also promote growth factor (e.g., FGF2) activity and thus stimulate endothelial growth and re-generation. It is a major component of basement membranes, where it is involved in the stabilization of other molecules as well as being involved with glomerular permeability to macromolecules and cell adhesion. Mutations in this gene cause Schwartz-Jampel syndrome type 1, Silverman-Handmaker type of dyssegmental dysplasia, and tardive dyskinesia. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014]

Uniprot Accession IDs

• P98160
• Q16287
• Q5SZI3
• Q9H3V5
• HSPG

Gene Name

• HSPG2

Ensembl ID

• ENST00000374695
• ENSP00000363827
• ENSG00000142798

Symbol

• PLC
• SJA
• SJS
• HSPG
• SJS1
• PRCAN

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
protein domain	1
cellular component	0.92
biological term	0.78
transcription factor	0.74
interacting protein	0.73

Protein Classes

PANTHER Classes

Protein / Receptor / Basement Membrane-specific Heparan Sulfate Proteoglycan Core Protein

Protein / Extracellular Matrix Protein / Extracellular Matrix Linker Protein / Basement Membrane-specific Heparan Sulfate Proteoglycan Core Protein

Protein / ... / Protease Inhibitor / Basement Membrane-specific Heparan Sulfate Proteoglycan Core Protein

DTO Classes

Protein / Enzyme Modulator / Protease Inhibitor / Basement Membrane-specific Heparan Sulfate Proteoglycan Core Protein

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 795.54   (req: < 5)

Gene RIFs: 102   (req: <= 3)

Antibodies: 445   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 795.54   (req: >= 5)

Gene RIFs: 102   (req: > 3)

Antibodies: 445   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 20

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0